Tuesday
SESSION 8: HOW SHOULD MOST PATIENTS WITH UNCOMPLICATED ACUTE TBAD BE TREATED: CONTROVERSY EXISTS AND WILL CONTINUE: THE PROS AND CONS OF EARLY TEVAR
SESSION 8 SCHEDULE
FOR EARLY TEVAR
4:48 PM - 4:53 PM Most Patients With Acute/Subacute Uncomplicated TBADs Should Undergo TEVAR: The INSTEAD-XL RCT Shows Better Long-Term Survival With TEVAR Than With Medical Treatment
  Presenter(s):Christoph A. Nienaber, MD, PhD  
  View Slides in PDF      
4:54 PM - 4:59 PM Most Patients With Acute Uncomplicated TBAD Should Receive TEVAR Treatment: I Have Said It Before Ė Now I Know It Is True And No More Trials Are Needed
  Presenter(s):Rodney A. White, MD  
5:00 PM - 5:05 PM Most Patients With Uncomplicated Acute TBAD Should Be Treated By TEVAR: Some Immediately And Some After A 6-12 Week Delay: How Can They Be Selected For Each Based On Data From The MOTHER Registry
  Presenter(s):Matt M. Thompson, MD  
  View Slides in PDF      
5:06 PM - 5:11 PM With Uncomplicated Acute TBAD There Is A High Risk Group That Should Be Treated By TEVAR: How Can They Be Selected And When Should They Be Treated
  Presenter(s):Michael D. Dake, MD  
  View Slides in PDF      
5:12 PM - 5:17 PM Medical Treatment Is Adequate For Most Patients With Uncomplicated TBAD Based On Current Long-Term Results
  Presenter(s):John A. Elefteriades, MD  
  View Slides in PDF      
5:18 PM - 5:23 PM The ADSORB Trial Tells Us What We Need To Know About Treating Uncomplicated TBADs: We Donít Need Further Trials
  Presenter(s):Jan S. Brunkwall, MD, PhD  
  View Slides in PDF      
5:24 PM - 5:29 PM We Still Need More Evidence Before We Treat Most Uncomplicated Acute/Subacute TBAD Patients With TEVAR
  Presenter(s):Michel Makaroun, MD  
  View Slides in PDF      
5:30 PM - 5:35 PM Why Wider Use Of TEVAR For Uncomplicated TBADs Right Now May Not Be So Good
  Presenter(s):Frank J. Criado, MD, FACS, FSVM  
  View Slides in PDF      
5:36 PM - 5:41 PM The INTACT-AD RCT Comparing TEVAR With Medical Treatment Will Give The Final Answer About The Best Treatment For Uncomplicated Acute/Subacute TBAD Patients: We Need This International Trial And How Will It Be Structured
  Presenter(s):Firas F. Mussa, MD / Christoph A. Nienaber, MD, PhD  
  View Slides in PDF      
5:42 PM - 5:50 PM Panel Discussion

End of Program A

END OF SESSION 8
previous next